AMEERA-5: A Randomized, Double-Blind Phase III Study of Amcenestrant + Palbociclib vs Letrozole + Palbociclib for Previously Untreated ER+/HER2- Advanced Breast Cancer

Sara Hurvitz, MD, reviews the implications of the AMEERA-5 trial, a randomized, double-blind phase III study of amcenestrant + palbociclib vs letrozole + palbociclib in the treatment of ER+/HER2- advanced breast cancer.

EP. 1: Understanding the Scope of ER+ Breast Cancer

June 30th 2021

Sara Hurvitz, MD, provides an overview of HR+ breast cancer.

EP. 2: Treatment Options For Advanced ER+ Breast Cancer

June 30th 2021

Sara Hurvitz, MD, discusses the therapeutic landscape for HR+ advanced breast cancer and considerations for treatment selection.

EP. 3: Safety and Efficacy of Amcenestrant in the AMEERA Trials

June 30th 2021

Sara Hurvitz, MD, reviews clinical trial data on amcenestrant, an orally administered endocrine therapy, in patients with ER+/HER2- breast cancer as shown in the AMEERA trials.

EP. 4: AMEERA-5: Key Data and Implications for Practice

June 30th 2021

An expert in breast oncology shares her thoughts on the importance of the AMEERA-5 findings to the evolving treatment landscape for HR+ breast cancer.

EP. 5: Potential Role for Amcenestrant in the Treatment of ER+/HER2- Advanced Breast Cancer

June 30th 2021

Sara Hurvitz, MD, provides insight on the potential role of amcenestrant in the treatment of HR+ breast cancer in the future.